###begin article-title 0
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 49 54 <span type="species:ncbi:9606">human</span>
Differential usage of alternate promoters of the human stress response gene ATF3 in stress response and cancer cells
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 585 589 570 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
###xml 997 1001 982 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1144 1148 1129 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 374 379 <span type="species:ncbi:9606">human</span>
###xml 384 389 <span type="species:ncbi:10090">mouse</span>
###xml 742 747 <span type="species:ncbi:9606">human</span>
Stress response gene ATF3 plays a pleiotropic role in determining cell fate in response to mitogenic or stress stimuli. An alternate promoter of the human ATF3 gene (designated P1 in this study) has recently been reported, which is located approximately43.5 kb upstream of the previously reported P2 promoter. We showed here that the P1 promoter is highly conserved between human and mouse and is functional in response to various stimuli, whereas the P1 promoter was dominantly induced by serum and the P2 promoter was more efficiently activated in response to TGF-beta and oncogenic HRAS. The P1 promoter contains multiple transcriptional start sites, and the different 5'-UTRs markedly affected their translation in response to stress. In human prostate and Hodgkin Reed-Sternberg cancer cells with elevated expression of ATF3, the P1 promoter was constitutively activated and its chromatin structure was modified into active configuration. The differential usage of alternate promoters of the ATF3 gene at both transcriptional and translational level and the modification of chromatin structure may provide a novel mechanism for expressing ATF3 in determining cell fate during stress response and cancer.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 755 760 755 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19</italic>
###xml 795 796 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 819 820 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1159 1162 1159 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5 B6 B7 B8">5&#8211;8</xref>
###xml 85 90 <span type="species:ncbi:9606">human</span>
An increasing number of studies demonstrate the existence of alternate promoters for human genes and their differential usage is one of important source for generating protein and regulatory diversity (1,2). For example, transcripts from alternate promoters are translated into distinct protein isoforms when their variant 5' exons contain alternative ATGs, producing proteins with different N-termini or different proteins. For many genes with multiple promoters, however, no variation in the resulting proteins is generated, when a common downstream exon contains the translation initiation site and generates the same open reading frame (ORF). Some of these alternate promoters have different tissue specificity and developmental activity, such as the CYP19 gene encoding the aromatase P450 (3) or glucokinase gene (4). Furthermore, mRNA variants transcribed from the alternate promoter cause difference of their translational efficiencies, since the variant 5'-UTRs regulate their secondary structure of mRNAs, thus affecting its stability and translation. The usage of alternate promoters of genes has also been reported to play role in stress response (5-8).
###end p 4
###begin p 5
###xml 359 364 359 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10 B11 B12 B13 B14">10&#8211;14</xref>
###xml 403 408 403 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15 B16 B17 B18 B19 B20 B21">15&#8211;21</xref>
###xml 442 446 442 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 542 546 542 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 728 732 728 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 797 799 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 864 869 864 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27 B28 B29">27&#8211;29</xref>
###xml 935 939 935 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 573 578 <span type="species:ncbi:9606">human</span>
###xml 653 658 <span type="species:ncbi:9606">human</span>
###xml 790 795 <span type="species:ncbi:10090">mouse</span>
Activating transcription factor (ATF) 3 is a member of the ATF/CREB family of basic-leucine zipper (b-Zip) type transcription factors. Its mRNA level is low or undetectable in most cells, but is greatly induced by a variety of stress signal (9-11, and references therein). This response has dual effects on cell fate, such as cell cycle arrest and apoptosis (10-14), or cell survival and proliferation (15-21). We have recently reported that ATF3 is induced downstream of c-myc in serum induction (22), and other laboratories showed that the ATF3 expression is elevated in human prostate (23) and Hodgkin Reed-Sternberg cells (24), and more recently in human breast cancer cells (25). Furthermore, transgenic over-expression of ATF3 in basal epithelial cells causes basal cell carcinoma in mouse (26). ATF3 also plays role as a negative regulator of inflammation (27-29). These data support both physiological and pathological role of ATF3 in regulating the stress response of cells to external stimuli.
###end p 5
###begin p 6
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 119 121 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 212 215 200 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 309 311 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 312 314 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 315 320 303 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30 B31 B32 B33 B34">30&#8211;34</xref>
###xml 481 485 469 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 530 532 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 475 480 <span type="species:ncbi:9606">human</span>
###xml 573 578 <span type="species:ncbi:9606">human</span>
###xml 583 588 <span type="species:ncbi:10090">mouse</span>
The human ATF3 gene is mapped to chromosome 1q32.3 region, and is comprised of five exons spanning approximately16 kb (30). The putative gene promoter, designated P2 in this study, contains a TATA motif and many cis-elements for binding of transcription factors responsible for the regulated gene expression (11,21,30-34). More recently, a large scale and genome-wide analysis of 5'-end sequence of full-length cDNAs has identified a novel upstream alternate promoter of the human ATF3 gene as deposited in Genbank (NM001030287) (35). We also identified the transcripts in human and mouse cells that contain various novel 5'-UTR (DDBJ/EMBL/GenBank with accession numbers AB291910, AB291911 and AB291912), but their functional and biological significance remains elusive.
###end p 6
###begin p 7
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 548 552 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 623 627 623 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 202 207 <span type="species:ncbi:9606">human</span>
###xml 212 217 <span type="species:ncbi:10090">mouse</span>
###xml 383 388 <span type="species:ncbi:9606">human</span>
###xml 542 547 <span type="species:ncbi:9606">human</span>
In this report, we investigated the molecular and functional properties of a novel upstream promoter, designated P1, of the human ATF3 gene. It is shown that the P1 promoter is highly conserved between human and mouse and is differentially used at both transcriptional and posttranscriptional level in stress response. More strikingly, the P1 promoter is constitutively activated in human cancer cells with elevated expression of ATF3. This study for the first time describes evidence for the differential usage of alternate promoters of the human ATF3 gene, providing a novel insight into the molecular mechanism by which ATF3 is induced in stress response and cancer.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Plasmids, antibodies and reagents
###end title 9
###begin p 10
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
###xml 776 777 770 771 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 778 779 772 773 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 248 254 <span type="species:ncbi:9986">rabbit</span>
###xml 814 819 <span type="species:ncbi:9606">human</span>
Plasmids encoding human HRAS wild-type and oncogenic mutant 12V were purchased from Addgene, and expression plasmids for oncogenic Ras 61L mutant and HA-Suv39 were gifts from Dr Nevins and Dr Jenuwein, respectively. Antibodies used were as follow: rabbit anti-ATF3 (C19, sc-188), anti-H-Ras (F235, sc-29), anti-RNA-polymerase II (N-20, sc-899) from Santa Cruz, anti-beta-actin (clone AC-74, A2228), anti-beta-tubulin (clone TUB2.1, T4026), anti-HA (clone HA-7) and anti-Flag (clone M2) from Sigma, anti-Leo-1 (A300-175A) from Bethyl, anti-H3-trimethyl-K4 (H3K4me3, ab8580) and anti-H3-trimethyl-K9 (H3K9me3, ab8898) from abcam, anti-acetyl-histone H3 (06-599) from Upstate. Doxorubicin, thapsigargin, tunicamycin, etoposide were from Sigma, methyl methanesulfonate (MMS) and H2O2 were nachalai tesque, recombinant human TGF-beta was from PeproTech. Other chemicals were reagents grade.
###end p 10
###begin title 11
Cell culture and treatments
###end title 11
###begin p 12
###xml 498 499 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 715 719 707 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
###xml 891 895 883 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 220 225 <span type="species:ncbi:9606">human</span>
###xml 243 248 <span type="species:ncbi:9606">human</span>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 325 330 <span type="species:ncbi:10090">mouse</span>
###xml 428 432 <span type="species:ncbi:9913">calf</span>
###xml 769 774 <span type="species:ncbi:10090">mouse</span>
Cell lines used in this study are HCT116 human colon carcinoma cell, U2OS human osteosarcoma cell, LNCaP, DU145, PC3 human prostate carcinoma cell (ATCC), L428 and L540 Hodgkin Reed-Sternberg cell (DSMZ, Germany), DAUDI human B cell and MOLT4 human T cell (RIKEN, Japan), HaCaT human keratinocyte (CLS, Germany). RAW264 is a mouse macrophage cell line (RIKEN, Japan). Cells were cultured in adequate media supplemented with 10% calf serum, 100 U/ml penicillin and 100 mug/ml streptomycin in a 5% CO2 atmosphere at 37degreesC. For induction by serum or various stimuli, cells were cultured in the presence of 0.5% serum for 48 h and induced by 20% serum, 100 mug/ml MMS or various agents. For expression of oncogene HRAS, neomycin-resistant U2OS cells stably expressing mouse ecotropic retrovirus receptor were infected by pMX retroviral vector encoding oncogenic mutants 12V, 61L, or normal HRAS and selected with 2 mug/ml puromycin. For transient expression, plasmid DNA was vortex-mixed with SuperFect (Qiagen) and transfected into cells according to manufacture's instruction.
###end p 12
###begin title 13
Cell extract preparation and western blot analysis
###end title 13
###begin p 14
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 168 174 <span type="species:ncbi:9913">bovine</span>
Cells treated as indicated were harvested, washed in PBS, and cell extracts were prepared as described (22). The amounts of protein were measured by Lowry method using bovine serum albumin as standard (36). Cell extracts (20 mug protein) were separated on an SDS-PAGE, transferred onto a nitrocellulose membrane, and subjected to western blot using the protocol of ECL kit (Amersham).
###end p 14
###begin title 15
RNA isolation and reverse transcription-PCR
###end title 15
###begin p 16
###xml 233 238 <span type="species:ncbi:9606">human</span>
###xml 334 339 <span type="species:ncbi:9606">human</span>
###xml 435 440 <span type="species:ncbi:10090">mouse</span>
###xml 535 540 <span type="species:ncbi:10090">mouse</span>
Total RNA was isolated by acid-guanidinium method using a kit from Qiagen. For detecting transcripts from P1 or P2 promoters of ATF3 gene, RT-PCR of 1 mug total RNA was performed using a kit from TaKaRa. Primers used were as follow: human P1 transcript, 5'-AGGATGCTCTGCTGTTTCCT-3' (forward) and 5'-TTAGCTCTGCAATGTTCCTTC-3' (reverse); human P2 transcript, 5'-TGATGCAACGCTCTCCAAGC-3' (forward) and 5'-TTAGCTCTGCAATGTTCCTTC-3' (reverse); mouse P1 transcript, 5'-AACAGGATCTCCCACAGGGT-3' (forward) and 5'-GACAAAGGGTGTCAGGTTAG-3' (reverse); mouse P2 transcript, 5'-CAGTGGAGCCAATCGGCTAA-3' (forward) and 5'-GACAAAGGGTGTCAGGTTAG-3' (reverse). Measurements of the ATF3 transcripts from the P1 and P2 promoters or GAPDH were also performed by quantitative RT-PCR. To this end, the efficiency of PCR-amplification of mRNA from each promoter was determined by control reaction using the plasmid DNA for each transcript, and used for calibration (). The data obtained were further normalized with that of GAPDH. Primers used were as follow: ATF3 (P1 transcript), 5'-AGGATGCTCTGCTGTTTCCT-3' (forward) and 5'-GACAAAGGGCGTCAGGTTAG-3' (reverse); ATF3 (P2 transcript), 5'-TGATGCAACGCTCTCCAAGC-3' (forward) and 5'-CAGAAGCACTCACTTCCGAG-3' (reverse); GAPDH, 5'-TGAAGGTCGGAGTCAACGGATTTGGT-3' (forward) and 5'-TTGATTTTGGSGGGATCTCG-3' (reverse).
###end p 16
###begin title 17
Primer extension analysis
###end title 17
###begin p 18
###xml 181 183 181 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 300 303 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
###xml 551 556 <span type="species:ncbi:9606">human</span>
Primer (5'-GGGCAAGGTGCTGAAAATCC-3') complementary to the region from +104 to +123 of the human ATF3 mRNA with novel 5'-UTR sequence in database (NM001030287) was radiolabeled with p32-gamma-ATP using T4 polynucleotide kinase, hybridized with PolyA mRNAs from serum-treated HCT116, and extended using AMV reverse transcriptase using a kit from Promega. Extended products were resolved on an 8% polyacrylamide sequencing gel. The sequence ladder was generated from the same primer using a template plasmid DNA containing upstream promoter region of the human ATF3 gene.
###end p 18
###begin title 19
5'-Rapid amplification of cDNA ends analysis
###end title 19
###begin p 20
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
###xml 346 351 <span type="species:ncbi:9606">human</span>
###xml 409 414 <span type="species:ncbi:10090">mouse</span>
###xml 532 537 <span type="species:ncbi:9606">human</span>
###xml 542 547 <span type="species:ncbi:10090">mouse</span>
Human HCT-116 and mouse RAW264 cells were treated with serum or MMS, and the 5'-ends of the ATF3 mRNA of the P1 promoter were determined by 5'-rapid amplification of cDNA end analysis (5'-RACE) using a kit from Invitrogen. ATF3 cDNA was amplified by PCR using a GeneRacer 5' primer or GeneRacer 5' nested primer and 3' primers specific for ATF3: human ATF3-3' reverse primer, 5'-CCTGGATGTTGAAGCATCATTTTGA-3'; mouse ATF3-3' reverse primer, 5'-TGGGATGAAGTGCTGGAACTC-3'. Multiple transcription start sites (TSSs) of the P1 promoter of human and mouse ATF3 genes have been deposited in DDBJ/EMBL/GenBank with accession numbers AB291910 and AB291911, respectively.
###end p 20
###begin title 21
RNAi experiments
###end title 21
###begin p 22
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
Mixtures of siRNA oligos (final concentration 100 nM) specific for the 5'-UTR of P1 or P2 transcript isoforms were transfected into HCT116 or LNCaP cells using X-tremeGENE transfection reagent (Roche), or into L428 and L540 Hodgkin Reed-Sternberg cells by electroporation as in ref. (24). HCT116 cells were then cultured in medium with 0.5% serum for 24 h, followed by stimulation with 20% serum or 100 mug/ml MMS. Sequences of siRNAs for the P1 5'-UTR were 5'-AGAGAAAUCCUCCUCUAUAUAGG-3' (83-105) and 5'-UUUCAGCACCUUGCCCCAAAAUC-3' (129-151), and those for the P2 5'-UTR were 5'-GCCAGCCUGAGGGCUAUAAAGG-3' (46-58), and 5'-CUCGCCCGCCGGCCAGACAAACA-3' (190-212). Control RNAi (siCtl) was a silencer negative control #1 (AM4611) from Ambion.
###end p 22
###begin title 23
Luciferase assay
###end title 23
###begin p 24
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 531 532 527 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 533 534 529 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 632 633 622 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 634 635 624 625 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 667 668 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 669 670 658 659 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 832 834 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 85 90 <span type="species:ncbi:9606">human</span>
Reporter plasmid, pLuc-P1ATF3 was constructed by subcloning a 2.1-kb fragment of the human ATF3 gene upstream promoter from -2091 to +9 (major TSS as +1) between Kpn1 and HindIII sites of pGL3 vector (Promega). pLuc-P2ATF3 reporter plasmid containing a 1850-bp region of P2 promoter was as described (11). Cells (5 x 104 cells) were transfected with 0.5 mug each reporter plasmid. At 16 h posttransfection, cells were starved with 0.5% serum for 48 h and then stimulated with 20% serum, 50 mug/ml MMS, 20 mug/ml etoposide, 50 muM H2O2, 1 muM doxorubicin, 2 muM thapsigargin, 1 muM tunicamycin or 100 pM TGF-beta For treatment with H2O2, cells were exposed to 50 muM H2O2 in PBS for 1 h, and then cultured in fresh medium containing serum. After cell culture for 16 h, extracts were assayed for the luciferase activity as described (11), using a Dual Luciferase Reporter Assay System according to the manufacture's protocol (Promega).
###end p 24
###begin title 25
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Translation in vitro and in vivo
###end title 25
###begin p 26
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 238 246 232 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 409 416 403 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 702 706 695 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
cDNAs for ATF3 transcripts with various UTRs were subcloned between Nhe1 and BamH1 sites of pcDNA3.1 expression vector. Each DNA (0.1 mug) was transcribed along with 0.2 mug vector encoding HA-Suv39 as an internal control in 10 microl of in vitro TNT assay kit driven by T7 RNA polymerase, followed by translation. ATF3 protein generated was quantitated by western blot and densitometric measurement. For the in vivo translation, the plasmid above (1 mug each) encoding the ATF3 protein tagged with Flag at the C-terminus was transfected into 293 cells and the expression of ATF3 protein was measured by western blot. Total RNA was also extracted, treated with RNase-free DNase (Sigma) and assayed for ATF3 mRNA generated from the transgene by quantitative RT-PCR. Primers used: 5'-CTGCAGAAAGAGTCGGAG-3' (forward, coding sequence of ATF3) and 5'-TAGAAGGCACAGTCGAGG-3' (reverse, BGH sequence of the vector).
###end p 26
###begin title 27
Chromatin immunoprecipitation assay
###end title 27
###begin p 28
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 230 234 230 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
Chromatin immunoprecipitation (ChIP) assays were performed as described (22) according to the protocol supplied by Upstate. ChIP DNA was detected using standard PCR with the following primer pairs for the different regions of the ATF3 gene: -5-kb region, 5'-TGGACACACACACGGAAACT-3' (forward) and 5'-GTCACATCTTCCCATCTGATC-3' (reverse), the P1 promoter region, 5'-AGGATGATGGAAGGCTGTCA-3' (forward) and 5'-GTCACATCTTCCCATCTGATC-3' (reverse), +10-kb region, 5'-TATGGGCTTTTGTTCGGGTTC-3' (forward) and 5'-TCAAAATGCGTGTGTGTGTG-3' (reverse), +20-kb region, 5'-AATGCCCTCACAGAAACACC-3' (forward) and 5'-GTTAGGCAGGAAGGGGAAAG-3' (reverse), +30-kb region, 5'-GGTGTGAATGTGCTTTGTGG-3' (forward) and 5'-AGAATCGGAATGGCTGTGAG-3' (reverse), the P2 promoter region (+40 kb), 5'-CGAACTTGCATCACCAGTGC-3' (forward) and 5'-GGTCGTTTACTCCGTGTTGC-3' (reverse), +50-kb region, 5'-ACATGTCCATCAGCTTCCAG-3' (forward) and 5'-CCACTGCTTGTGGATTAAGG-3' (reverse), +55-kb region, 5'-ACCTGTTCCCCATGGATGTA-3' (forward) and 5'-TGTGTCAGGGAGCCCAAATA-3' (reverse).
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 67 75 67 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 171 172 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Multiple comparisons were evaluated by ANOVA followed by Scheffe's post hoc test. Data are presented as mean +/- SD. Statistical significance was assigned at the level of P < 0.05.
###end p 30
###begin title 31
RESULTS
###end title 31
###begin title 32
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
The upstream alternate promoter P1 is conserved between human and mouse
###end title 32
###begin p 33
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 135 143 135 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 310 318 310 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 495 503 495 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 810 812 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 813 815 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 989 997 977 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1251 1259 1239 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1371 1380 1359 1368 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 1435 1439 1423 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1466 1467 1454 1455 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1534 1538 1522 1526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1644 1646 1632 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 1678 1680 1666 1668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1698 1699 1686 1687 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1854 1855 1842 1843 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1876 1877 1864 1865 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1380 2006 1368 1994 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="34">Conservation of the upstream alternate promoter of the <italic>ATF3</italic> gene in human and mouse. (<bold>A</bold>) Schematic representation of the structure of the human and mouse <italic>ATF3</italic> genes. Exon A is further devided into A-1 and A corresponding to the novel promoter recently identified (<xref ref-type="bibr" rid="B35">35</xref>) and that previously reported (<xref ref-type="bibr" rid="B27">27</xref>), respectively. (<bold>B</bold>) Total RNAs from serum-induced human HCT116 or mouse RAW264 cells were assayed for the expression of transcripts containing the exon A-1 or A by RT&#8211;PCR. (<bold>C</bold>) Specific bands in (<bold>B</bold>) were subcloned, sequenced and the nucleotide sequences of the junction between the exon A-1 and B of human and mouse are shown.</p>
###xml 1380 2006 1368 1994 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="34">Conservation of the upstream alternate promoter of the <italic>ATF3</italic> gene in human and mouse. (<bold>A</bold>) Schematic representation of the structure of the human and mouse <italic>ATF3</italic> genes. Exon A is further devided into A-1 and A corresponding to the novel promoter recently identified (<xref ref-type="bibr" rid="B35">35</xref>) and that previously reported (<xref ref-type="bibr" rid="B27">27</xref>), respectively. (<bold>B</bold>) Total RNAs from serum-induced human HCT116 or mouse RAW264 cells were assayed for the expression of transcripts containing the exon A-1 or A by RT&#8211;PCR. (<bold>C</bold>) Specific bands in (<bold>B</bold>) were subcloned, sequenced and the nucleotide sequences of the junction between the exon A-1 and B of human and mouse are shown.</p></caption>
###xml 2006 2006 1994 1994 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn1082f1"/>
###xml 1371 2006 1359 1994 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="34">Conservation of the upstream alternate promoter of the <italic>ATF3</italic> gene in human and mouse. (<bold>A</bold>) Schematic representation of the structure of the human and mouse <italic>ATF3</italic> genes. Exon A is further devided into A-1 and A corresponding to the novel promoter recently identified (<xref ref-type="bibr" rid="B35">35</xref>) and that previously reported (<xref ref-type="bibr" rid="B27">27</xref>), respectively. (<bold>B</bold>) Total RNAs from serum-induced human HCT116 or mouse RAW264 cells were assayed for the expression of transcripts containing the exon A-1 or A by RT&#8211;PCR. (<bold>C</bold>) Specific bands in (<bold>B</bold>) were subcloned, sequenced and the nucleotide sequences of the junction between the exon A-1 and B of human and mouse are shown.</p></caption><graphic xlink:href="gkn1082f1"/></fig>
###xml 2006 2015 1994 2003 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 2060 2064 2048 2052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 2072 2073 2060 2061 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2144 2148 2132 2136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 2568 2569 2554 2555 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2650 2654 2636 2640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 2015 2963 2003 2949 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="35">Structure of the upstream promoter P1 of the <italic>ATF3</italic> gene. (<bold>A</bold>) Primer extension analysis of mRNAs from the P1 promoter of the human <italic>ATF3</italic> gene. A primer specific for the P1 transcript was annealed to 1 &#956;g of polyA mRNAs isolated from the serum-treated HCT116 cells (lane 5), 1 &#956;g yeast tRNA (lane 6) or none (lane 7), and the TSSs were determined as in Materials and methods section. Lanes 1&#8211;4 represent a sequence ladder. The arrows on the right indicate the TSSs, and the sequence is shown on the left. Bold letters represent multiple TSSs identified. (<bold>B</bold>) Alignment of the nucleotide sequence of the P1 promoter of the human and mouse <italic>ATF3</italic> gene. Arrows indicate the multiple TSSs, and the numbers in parentheses represent the clones analyzed by 5&#8242;-RACE of the serum-stimulated cells. Putative TATA box is shown in the box. Multiple TSSs of the human and mouse genes were deposited in DDBJ with accession numbers AB291910 and AB291911, respectively.</p>
###xml 2015 2963 2003 2949 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="35">Structure of the upstream promoter P1 of the <italic>ATF3</italic> gene. (<bold>A</bold>) Primer extension analysis of mRNAs from the P1 promoter of the human <italic>ATF3</italic> gene. A primer specific for the P1 transcript was annealed to 1 &#956;g of polyA mRNAs isolated from the serum-treated HCT116 cells (lane 5), 1 &#956;g yeast tRNA (lane 6) or none (lane 7), and the TSSs were determined as in Materials and methods section. Lanes 1&#8211;4 represent a sequence ladder. The arrows on the right indicate the TSSs, and the sequence is shown on the left. Bold letters represent multiple TSSs identified. (<bold>B</bold>) Alignment of the nucleotide sequence of the P1 promoter of the human and mouse <italic>ATF3</italic> gene. Arrows indicate the multiple TSSs, and the numbers in parentheses represent the clones analyzed by 5&#8242;-RACE of the serum-stimulated cells. Putative TATA box is shown in the box. Multiple TSSs of the human and mouse genes were deposited in DDBJ with accession numbers AB291910 and AB291911, respectively.</p></caption>
###xml 2963 2963 2949 2949 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn1082f2"/>
###xml 2006 2963 1994 2949 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="35">Structure of the upstream promoter P1 of the <italic>ATF3</italic> gene. (<bold>A</bold>) Primer extension analysis of mRNAs from the P1 promoter of the human <italic>ATF3</italic> gene. A primer specific for the P1 transcript was annealed to 1 &#956;g of polyA mRNAs isolated from the serum-treated HCT116 cells (lane 5), 1 &#956;g yeast tRNA (lane 6) or none (lane 7), and the TSSs were determined as in Materials and methods section. Lanes 1&#8211;4 represent a sequence ladder. The arrows on the right indicate the TSSs, and the sequence is shown on the left. Bold letters represent multiple TSSs identified. (<bold>B</bold>) Alignment of the nucleotide sequence of the P1 promoter of the human and mouse <italic>ATF3</italic> gene. Arrows indicate the multiple TSSs, and the numbers in parentheses represent the clones analyzed by 5&#8242;-RACE of the serum-stimulated cells. Putative TATA box is shown in the box. Multiple TSSs of the human and mouse genes were deposited in DDBJ with accession numbers AB291910 and AB291911, respectively.</p></caption><graphic xlink:href="gkn1082f2"/></fig>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 209 214 <span type="species:ncbi:9606">human</span>
###xml 580 585 <span type="species:ncbi:10090">mouse</span>
###xml 669 674 <span type="species:ncbi:10090">mouse</span>
###xml 710 715 <span type="species:ncbi:9606">human</span>
###xml 720 725 <span type="species:ncbi:10090">mouse</span>
###xml 973 978 <span type="species:ncbi:10090">mouse</span>
###xml 1052 1057 <span type="species:ncbi:9606">human</span>
###xml 1062 1067 <span type="species:ncbi:10090">mouse</span>
###xml 1202 1207 <span type="species:ncbi:9606">human</span>
###xml 1212 1217 <span type="species:ncbi:10090">mouse</span>
###xml 1354 1359 <span type="species:ncbi:9606">human</span>
###xml 1364 1369 <span type="species:ncbi:10090">mouse</span>
###xml 1448 1453 <span type="species:ncbi:9606">human</span>
###xml 1458 1463 <span type="species:ncbi:10090">mouse</span>
###xml 1518 1523 <span type="species:ncbi:9606">human</span>
###xml 1528 1533 <span type="species:ncbi:10090">mouse</span>
###xml 1731 1736 <span type="species:ncbi:9606">human</span>
###xml 1747 1752 <span type="species:ncbi:10090">mouse</span>
###xml 1980 1985 <span type="species:ncbi:9606">human</span>
###xml 1990 1995 <span type="species:ncbi:10090">mouse</span>
###xml 2138 2143 <span type="species:ncbi:9606">human</span>
###xml 2293 2298 <span type="species:ncbi:4932">yeast</span>
###xml 2634 2639 <span type="species:ncbi:9606">human</span>
###xml 2644 2649 <span type="species:ncbi:10090">mouse</span>
###xml 2859 2864 <span type="species:ncbi:9606">human</span>
###xml 2869 2874 <span type="species:ncbi:10090">mouse</span>
It has recently been demonstrated that the human ATF3 gene contains an alternate promoter (Genbank accession number NM001030287) (35). Figure 1B, upper panel, showed two different products were amplified from human cells by RT-PCR using two different 5' primers, which located at exon A-1 or canonical exon A (Figure 1A), respectively. These bands were only detected after the synthesis of the first strand cDNA using oligo-dT primer, indicating that they were derived from the matured mRNA. In Figure 1B, lower panel, a specific band was also amplified by RT-PCR of total RNA of mouse RAW264 cells using a 5' primer located at the approximately34.5-kb upstream of the mouse exon A. Sequence analysis of these human and mouse transcripts revealed that the longer bands correspond to those previously reported (37,38), but the shorter ones contained novel 5'-UTRs representing the transcripts from the upstream promoter (DDBJ/EMBL/GenBank with accession number AB291912 for mouse atf3). In Figure 1C, the sequence comparison of the novel transcripts of human and mouse showed that the junction of the upstream exon A-1 and exon B are nearly identical. Moreover, the nucleotide sequence alignment of the human and mouse P1 promoter shows high homology (Figure 2B). Taken together, these data indicate that the novel P1 promoter is highly conserved between human and mouse. Figure 1.Conservation of the upstream alternate promoter of the ATF3 gene in human and mouse. (A) Schematic representation of the structure of the human and mouse ATF3 genes. Exon A is further devided into A-1 and A corresponding to the novel promoter recently identified (35) and that previously reported (27), respectively. (B) Total RNAs from serum-induced human HCT116 or mouse RAW264 cells were assayed for the expression of transcripts containing the exon A-1 or A by RT-PCR. (C) Specific bands in (B) were subcloned, sequenced and the nucleotide sequences of the junction between the exon A-1 and B of human and mouse are shown.Figure 2.Structure of the upstream promoter P1 of the ATF3 gene. (A) Primer extension analysis of mRNAs from the P1 promoter of the human ATF3 gene. A primer specific for the P1 transcript was annealed to 1 mug of polyA mRNAs isolated from the serum-treated HCT116 cells (lane 5), 1 mug yeast tRNA (lane 6) or none (lane 7), and the TSSs were determined as in Materials and methods section. Lanes 1-4 represent a sequence ladder. The arrows on the right indicate the TSSs, and the sequence is shown on the left. Bold letters represent multiple TSSs identified. (B) Alignment of the nucleotide sequence of the P1 promoter of the human and mouse ATF3 gene. Arrows indicate the multiple TSSs, and the numbers in parentheses represent the clones analyzed by 5'-RACE of the serum-stimulated cells. Putative TATA box is shown in the box. Multiple TSSs of the human and mouse genes were deposited in DDBJ with accession numbers AB291910 and AB291911, respectively.
###end p 33
###begin p 34
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 86 87 86 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 318 319 318 319 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 474 475 474 475 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 496 497 496 497 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
###xml 138 143 <span type="species:ncbi:9606">human</span>
###xml 148 153 <span type="species:ncbi:10090">mouse</span>
###xml 351 356 <span type="species:ncbi:9606">human</span>
###xml 367 372 <span type="species:ncbi:10090">mouse</span>
###xml 600 605 <span type="species:ncbi:9606">human</span>
###xml 610 615 <span type="species:ncbi:10090">mouse</span>
Conservation of the upstream alternate promoter of the ATF3 gene in human and mouse. (A) Schematic representation of the structure of the human and mouse ATF3 genes. Exon A is further devided into A-1 and A corresponding to the novel promoter recently identified (35) and that previously reported (27), respectively. (B) Total RNAs from serum-induced human HCT116 or mouse RAW264 cells were assayed for the expression of transcripts containing the exon A-1 or A by RT-PCR. (C) Specific bands in (B) were subcloned, sequenced and the nucleotide sequences of the junction between the exon A-1 and B of human and mouse are shown.
###end p 34
###begin p 35
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 57 58 57 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 553 554 551 552 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 635 639 633 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 123 128 <span type="species:ncbi:9606">human</span>
###xml 278 283 <span type="species:ncbi:4932">yeast</span>
###xml 619 624 <span type="species:ncbi:9606">human</span>
###xml 629 634 <span type="species:ncbi:10090">mouse</span>
###xml 844 849 <span type="species:ncbi:9606">human</span>
###xml 854 859 <span type="species:ncbi:10090">mouse</span>
Structure of the upstream promoter P1 of the ATF3 gene. (A) Primer extension analysis of mRNAs from the P1 promoter of the human ATF3 gene. A primer specific for the P1 transcript was annealed to 1 mug of polyA mRNAs isolated from the serum-treated HCT116 cells (lane 5), 1 mug yeast tRNA (lane 6) or none (lane 7), and the TSSs were determined as in Materials and methods section. Lanes 1-4 represent a sequence ladder. The arrows on the right indicate the TSSs, and the sequence is shown on the left. Bold letters represent multiple TSSs identified. (B) Alignment of the nucleotide sequence of the P1 promoter of the human and mouse ATF3 gene. Arrows indicate the multiple TSSs, and the numbers in parentheses represent the clones analyzed by 5'-RACE of the serum-stimulated cells. Putative TATA box is shown in the box. Multiple TSSs of the human and mouse genes were deposited in DDBJ with accession numbers AB291910 and AB291911, respectively.
###end p 35
###begin title 36
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
The upstream alternate promoter P1 contains multiple TSSs in human and mouse
###end title 36
###begin p 37
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 176 184 176 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 420 428 420 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 683 691 683 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 151 156 <span type="species:ncbi:9606">human</span>
###xml 664 669 <span type="species:ncbi:10090">mouse</span>
###xml 771 776 <span type="species:ncbi:9606">human</span>
###xml 781 786 <span type="species:ncbi:10090">mouse</span>
To determine the TSSs from the P1 promoter of the human ATF3 gene, we first performed a primer extension analysis using mRNA from the serum-stimulated human cells. As shown in Figure 2A, several extended products, one major and at least three minor bands were identified, indicating the presence of multiple TSSs from the P1 promoter. We further performed a 5'-RACE assay to determine the 5'-end(s) of ATF3 transcripts. Figure 2B showed that multiple TSSs determined by 5'-RACE coincided with those by primer extension, indicating the isolation of intact mRNA and the complete reaction by reverse transcriptase. Multiple initiation sites were also observed in the mouse P1 promoter (Figure 2B). From the sequence homology of the P1 promoter and the multiple TSSs between human and mouse, it is speculated that ATAAA sequence at approximately30-bp upstream from the major start site is functional as putative TATA motif. Further, we observed other binding motifs for ATF/CRE, AP1, p53, E2F or NF-kB within the 2-kb upstream region of the P1 promoter (data not shown).
###end p 37
###begin title 38
Differential response of the alternate promoters P1 and P2 to various stimuli
###end title 38
###begin p 39
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 237 245 237 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 658 666 658 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1112 1120 1112 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1179 1180 1179 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1181 1182 1181 1182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1261 1263 1258 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1278 1282 1275 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
###xml 1284 1286 1281 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1740 1748 1734 1742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1933 1937 1927 1931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 2053 2062 2047 2056 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 2137 2138 2131 2132 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2589 2590 2582 2583 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2868 2869 2861 2862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2907 2908 2900 2901 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2978 2979 2969 2970 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2980 2981 2971 2972 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3278 3282 3263 3267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
###xml 3303 3304 3288 3289 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 3563 3567 3548 3552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
###xml 2062 3747 2056 3732 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="40">Differential response of the ATF3 alternate promoters to various stimuli. (<bold>A</bold>) HCT116 cells were serum-starved in the presence of 0.5% serum for 48 h, and then stimulated by 20% serum, or 100 &#956;g/ml MMS. At each time indicated, the ATF3 mRNA isoforms from the P1 (filled circle) or P2 promoter (filled square) was measured. Relative expression of these transcripts was normalized to GAPDH as in Materials and methods section and Supplementary Figure S1. Lower panel shows a regular RT&#8211;PCR gel of the representative experiment. (<bold>B</bold>) HCT116 cells transfected with siRNA oligos control (siCtl), specific for the P1 (siP1) or P2 transcript (siP2) were stimulated with serum or MMS as in Materials and method section. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. *<italic>P</italic> &lt; 0.05 compared with control siCtl. (<bold>C</bold>) HCT116 cells were treated with 20 &#956;g/ml etoposide (Etopo), 50 &#956;M H<sub>2</sub>O<sub>2</sub>, 1 &#956;M doxorubicin (Dox), 2 &#956;M thapsigargin (Thap), 1 &#956;M tunicamycin (Tuni) and HaCaT cells were treated with 100 pM TGF-&#946;. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. U2OS cells stably expressing the normal, oncogenic 12V or 61L mutants of <italic>HRAS</italic> were also assayed. (<bold>D</bold>) Cells transfected with pLuc-P1ATF3 (closed) or pLuc-P2ATF3 (open) were treated with various agents as in (C) for 16 h and assayed for luciferase activity. Data represent the fold induction compared to unstimulated cells. For U2OS cells expressing oncogenic <italic>HRAS</italic>, the fold induction of activity compared to the empty vector is shown. All the data from (A) through (D) represent means with standard error bars of three independent experiments.</p>
###xml 2062 3747 2056 3732 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="40">Differential response of the ATF3 alternate promoters to various stimuli. (<bold>A</bold>) HCT116 cells were serum-starved in the presence of 0.5% serum for 48 h, and then stimulated by 20% serum, or 100 &#956;g/ml MMS. At each time indicated, the ATF3 mRNA isoforms from the P1 (filled circle) or P2 promoter (filled square) was measured. Relative expression of these transcripts was normalized to GAPDH as in Materials and methods section and Supplementary Figure S1. Lower panel shows a regular RT&#8211;PCR gel of the representative experiment. (<bold>B</bold>) HCT116 cells transfected with siRNA oligos control (siCtl), specific for the P1 (siP1) or P2 transcript (siP2) were stimulated with serum or MMS as in Materials and method section. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. *<italic>P</italic> &lt; 0.05 compared with control siCtl. (<bold>C</bold>) HCT116 cells were treated with 20 &#956;g/ml etoposide (Etopo), 50 &#956;M H<sub>2</sub>O<sub>2</sub>, 1 &#956;M doxorubicin (Dox), 2 &#956;M thapsigargin (Thap), 1 &#956;M tunicamycin (Tuni) and HaCaT cells were treated with 100 pM TGF-&#946;. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. U2OS cells stably expressing the normal, oncogenic 12V or 61L mutants of <italic>HRAS</italic> were also assayed. (<bold>D</bold>) Cells transfected with pLuc-P1ATF3 (closed) or pLuc-P2ATF3 (open) were treated with various agents as in (C) for 16 h and assayed for luciferase activity. Data represent the fold induction compared to unstimulated cells. For U2OS cells expressing oncogenic <italic>HRAS</italic>, the fold induction of activity compared to the empty vector is shown. All the data from (A) through (D) represent means with standard error bars of three independent experiments.</p></caption>
###xml 3747 3747 3732 3732 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn1082f3a"/>
###xml 3747 3747 3732 3732 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn1082f3b"/>
###xml 2053 3747 2047 3732 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="40">Differential response of the ATF3 alternate promoters to various stimuli. (<bold>A</bold>) HCT116 cells were serum-starved in the presence of 0.5% serum for 48 h, and then stimulated by 20% serum, or 100 &#956;g/ml MMS. At each time indicated, the ATF3 mRNA isoforms from the P1 (filled circle) or P2 promoter (filled square) was measured. Relative expression of these transcripts was normalized to GAPDH as in Materials and methods section and Supplementary Figure S1. Lower panel shows a regular RT&#8211;PCR gel of the representative experiment. (<bold>B</bold>) HCT116 cells transfected with siRNA oligos control (siCtl), specific for the P1 (siP1) or P2 transcript (siP2) were stimulated with serum or MMS as in Materials and method section. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. *<italic>P</italic> &lt; 0.05 compared with control siCtl. (<bold>C</bold>) HCT116 cells were treated with 20 &#956;g/ml etoposide (Etopo), 50 &#956;M H<sub>2</sub>O<sub>2</sub>, 1 &#956;M doxorubicin (Dox), 2 &#956;M thapsigargin (Thap), 1 &#956;M tunicamycin (Tuni) and HaCaT cells were treated with 100 pM TGF-&#946;. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. U2OS cells stably expressing the normal, oncogenic 12V or 61L mutants of <italic>HRAS</italic> were also assayed. (<bold>D</bold>) Cells transfected with pLuc-P1ATF3 (closed) or pLuc-P2ATF3 (open) were treated with various agents as in (C) for 16 h and assayed for luciferase activity. Data represent the fold induction compared to unstimulated cells. For U2OS cells expressing oncogenic <italic>HRAS</italic>, the fold induction of activity compared to the empty vector is shown. All the data from (A) through (D) represent means with standard error bars of three independent experiments.</p></caption><graphic xlink:href="gkn1082f3a"/><graphic xlink:href="gkn1082f3b"/></fig>
###xml 1427 1432 <span type="species:ncbi:9606">human</span>
Stress response gene ATF3 is activated by not only stress but also mitogenic stimuli such as serum, epidermal growth factor or fibroblast growth factor (16,17). As shown in , ATF3 mRNA and protein was induced by serum and MMS treatment. Figure 3A showed that both the P1 and P2 transcript isoforms were induced to a similar extent by MMS treatment. In contrast, the P1 transcript was significantly induced by serum, whereas the induction of P2 transcript was more rapid but decreased earlier than the P1 transcript. To clarify the involvement of each promoter, we knocked down the P1 or P2 transcript by RNA interference-mediated gene silencing. As shown in Figure 3B, the knockdown of the P1 or P2 transcript partially suppressed the induction of ATF3 protein in response to MMS, demonstrating the contribution of both promoters. In contrast, in serum-stimulated cells, only the knockdown of the P1 transcript significantly reduced the ATF3 induction, clearly defining the direct contribution of the P1 promoter in serum induction. Next, we addressed if the P1 and P2 transcripts were induced by other stimuli. Figure 3C showed that both transcripts were induced by etoposide, H2O2, doxorubicin, thapsigargin and tunicamycin. ATF3 is also induced by TGF-beta (13) or oncogenic HRAS (14), which mediates suppression of cell proliferation, tumor growth or cell senescence. Both the P1 and P2 isoforms were also induced in HaCaT human keratinocytes stimulated with TGF-beta or in cells stably expressing oncogenic HRAS 12V or 61L, but not normal HRAS. The induction of the P2 transcript dominated that of the P1 transcript in these cells. Further, we examined the activation of the P1 and P2 promoter by these stimuli using a reporter assay. Figure 3D clearly showed both the P1 and P2 reporter activities were induced in response to these stimuli. Taken together, these data demonstrate that the upstream alternate promoter P1 of the ATF3 gene is activated at the transcriptional level by various stimuli, but differently from the canonical P2 promoter. Figure 3.Differential response of the ATF3 alternate promoters to various stimuli. (A) HCT116 cells were serum-starved in the presence of 0.5% serum for 48 h, and then stimulated by 20% serum, or 100 mug/ml MMS. At each time indicated, the ATF3 mRNA isoforms from the P1 (filled circle) or P2 promoter (filled square) was measured. Relative expression of these transcripts was normalized to GAPDH as in Materials and methods section and Supplementary Figure S1. Lower panel shows a regular RT-PCR gel of the representative experiment. (B) HCT116 cells transfected with siRNA oligos control (siCtl), specific for the P1 (siP1) or P2 transcript (siP2) were stimulated with serum or MMS as in Materials and method section. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. *P < 0.05 compared with control siCtl. (C) HCT116 cells were treated with 20 mug/ml etoposide (Etopo), 50 muM H2O2, 1 muM doxorubicin (Dox), 2 muM thapsigargin (Thap), 1 muM tunicamycin (Tuni) and HaCaT cells were treated with 100 pM TGF-beta. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. U2OS cells stably expressing the normal, oncogenic 12V or 61L mutants of HRAS were also assayed. (D) Cells transfected with pLuc-P1ATF3 (closed) or pLuc-P2ATF3 (open) were treated with various agents as in (C) for 16 h and assayed for luciferase activity. Data represent the fold induction compared to unstimulated cells. For U2OS cells expressing oncogenic HRAS, the fold induction of activity compared to the empty vector is shown. All the data from (A) through (D) represent means with standard error bars of three independent experiments.
###end p 39
###begin p 40
###xml 75 76 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 527 528 526 527 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 806 807 805 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 845 846 844 845 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 916 917 913 914 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 918 919 915 916 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1216 1220 1207 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
###xml 1241 1242 1232 1233 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1501 1505 1492 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
Differential response of the ATF3 alternate promoters to various stimuli. (A) HCT116 cells were serum-starved in the presence of 0.5% serum for 48 h, and then stimulated by 20% serum, or 100 mug/ml MMS. At each time indicated, the ATF3 mRNA isoforms from the P1 (filled circle) or P2 promoter (filled square) was measured. Relative expression of these transcripts was normalized to GAPDH as in Materials and methods section and Supplementary Figure S1. Lower panel shows a regular RT-PCR gel of the representative experiment. (B) HCT116 cells transfected with siRNA oligos control (siCtl), specific for the P1 (siP1) or P2 transcript (siP2) were stimulated with serum or MMS as in Materials and method section. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. *P < 0.05 compared with control siCtl. (C) HCT116 cells were treated with 20 mug/ml etoposide (Etopo), 50 muM H2O2, 1 muM doxorubicin (Dox), 2 muM thapsigargin (Thap), 1 muM tunicamycin (Tuni) and HaCaT cells were treated with 100 pM TGF-beta. At each time indicated, the expression of the P1, P2 transcript or ATF3 protein was measured. U2OS cells stably expressing the normal, oncogenic 12V or 61L mutants of HRAS were also assayed. (D) Cells transfected with pLuc-P1ATF3 (closed) or pLuc-P2ATF3 (open) were treated with various agents as in (C) for 16 h and assayed for luciferase activity. Data represent the fold induction compared to unstimulated cells. For U2OS cells expressing oncogenic HRAS, the fold induction of activity compared to the empty vector is shown. All the data from (A) through (D) represent means with standard error bars of three independent experiments.
###end p 40
###begin title 41
Regulation of translation by 5'-UTR of the transcripts from the P1 promoter
###end title 41
###begin p 42
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 570 578 546 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 803 811 779 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 885 893 861 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1009 1016 985 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1108 1116 1084 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1118 1126 1094 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1338 1346 1314 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1697 1706 1673 1682 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 1739 1743 1715 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1789 1790 1765 1766 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2038 2046 2014 2022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2150 2152 2126 2128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 2156 2157 2132 2133 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2192 2200 2168 2176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2330 2331 2306 2307 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2643 2644 2619 2620 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1706 3036 1682 3011 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="43">Efficiency of translation of the <italic>ATF3</italic> mRNA isoforms from the P1 and P2 promoters. (<bold>A</bold>) Expression reporter plasmids encoding the ATF3 transcripts with various 5&#8242;-UTRs from the P1 (upper panel) and P2 promoters (lower panel) are shown. Arrows a through e indicate the 5&#8242;-ends of mRNAs corresponding multiple TSS of the P1 promoter in <xref ref-type="fig" rid="F2">Figure 2</xref>B, and arrows a and b indicate the 5&#8242;-ends the P2 transcripts obtained from the database and reference (<xref ref-type="bibr" rid="B27">27</xref>). (<bold>B</bold>) Each plasmid was assayed for the <italic>in vitro</italic> translation as described in the Materials and methods section. The relative expression of ATF3 to plasmid without UTR is shown. (<bold>C</bold>) 293 cells were transfected with each expression plasmid, cultured for 24 h, and the ATF3 mRNA and protein generated from the transgene was measured as in the Materials and methods section. Relative efficiency of translation is the ratio of the ATF3 protein normalized to mRNA compared to that without 5&#8242;-UTR. (<bold>D</bold>) 293 cells were transfected with each plasmid, starved with 0.5% serum, followed by stimulation with 20% serum for 24 h or 50 &#956;g/ml MMS for 12 h. After measurement of both ATF3 protein and mRNA generated from the transgene, relative efficiency of translation is shown as in (C). All the data from (B) through (D) represent the means with standard error bar of three independent experiments.</p>
###xml 1706 3036 1682 3011 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="43">Efficiency of translation of the <italic>ATF3</italic> mRNA isoforms from the P1 and P2 promoters. (<bold>A</bold>) Expression reporter plasmids encoding the ATF3 transcripts with various 5&#8242;-UTRs from the P1 (upper panel) and P2 promoters (lower panel) are shown. Arrows a through e indicate the 5&#8242;-ends of mRNAs corresponding multiple TSS of the P1 promoter in <xref ref-type="fig" rid="F2">Figure 2</xref>B, and arrows a and b indicate the 5&#8242;-ends the P2 transcripts obtained from the database and reference (<xref ref-type="bibr" rid="B27">27</xref>). (<bold>B</bold>) Each plasmid was assayed for the <italic>in vitro</italic> translation as described in the Materials and methods section. The relative expression of ATF3 to plasmid without UTR is shown. (<bold>C</bold>) 293 cells were transfected with each expression plasmid, cultured for 24 h, and the ATF3 mRNA and protein generated from the transgene was measured as in the Materials and methods section. Relative efficiency of translation is the ratio of the ATF3 protein normalized to mRNA compared to that without 5&#8242;-UTR. (<bold>D</bold>) 293 cells were transfected with each plasmid, starved with 0.5% serum, followed by stimulation with 20% serum for 24 h or 50 &#956;g/ml MMS for 12 h. After measurement of both ATF3 protein and mRNA generated from the transgene, relative efficiency of translation is shown as in (C). All the data from (B) through (D) represent the means with standard error bar of three independent experiments.</p></caption>
###xml 3036 3036 3011 3011 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn1082f4a"/>
###xml 3036 3036 3011 3011 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn1082f4b"/>
###xml 1697 3036 1673 3011 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="43">Efficiency of translation of the <italic>ATF3</italic> mRNA isoforms from the P1 and P2 promoters. (<bold>A</bold>) Expression reporter plasmids encoding the ATF3 transcripts with various 5&#8242;-UTRs from the P1 (upper panel) and P2 promoters (lower panel) are shown. Arrows a through e indicate the 5&#8242;-ends of mRNAs corresponding multiple TSS of the P1 promoter in <xref ref-type="fig" rid="F2">Figure 2</xref>B, and arrows a and b indicate the 5&#8242;-ends the P2 transcripts obtained from the database and reference (<xref ref-type="bibr" rid="B27">27</xref>). (<bold>B</bold>) Each plasmid was assayed for the <italic>in vitro</italic> translation as described in the Materials and methods section. The relative expression of ATF3 to plasmid without UTR is shown. (<bold>C</bold>) 293 cells were transfected with each expression plasmid, cultured for 24 h, and the ATF3 mRNA and protein generated from the transgene was measured as in the Materials and methods section. Relative efficiency of translation is the ratio of the ATF3 protein normalized to mRNA compared to that without 5&#8242;-UTR. (<bold>D</bold>) 293 cells were transfected with each plasmid, starved with 0.5% serum, followed by stimulation with 20% serum for 24 h or 50 &#956;g/ml MMS for 12 h. After measurement of both ATF3 protein and mRNA generated from the transgene, relative efficiency of translation is shown as in (C). All the data from (B) through (D) represent the means with standard error bar of three independent experiments.</p></caption><graphic xlink:href="gkn1082f4a"/><graphic xlink:href="gkn1082f4b"/></fig>
Figure 4A and  showed that the 5'-UTR of the P1 transcripts has unique structural properties; multiple TSSs, less score of GC content (approximately50%), and five upstream AUG (uAUGs) compared to the P2 transcripts; two TSSs, higher GC content (approximately70%), and one upstream AUG (uAUGs). Moreover, the 5'-RACE analysis revealed that multiple TSSs of the P1 promoter were differently used in MMS-treated HCT116 cells from serum-stimulated cells; the number ratio of clones obtained were 6:12:12:0 (b:c:d:e) in MMS-cells compared to 3:2:20:2 in serum response as in Figure 2B. To explore the possible effect of different 5'-UTRs on the translational efficiency, we performed a translational reporter assay using the ATF3 expression plasmids containing different 5'-UTR of the P1 and P2 transcripts. Figure 4B showed that most of the P1 and P2 constructs generated the ATF3 protein in vitro with an apparently comparable efficiency, except for the long 5'-UTR P2 transcript. The relative efficiency of the in vivo translation of various reporters in unstimulated 293 cells appeared to be similar to those in vitro (Figure 4C). In contrast, in cells treated by serum or MMS, the translation of the reporters P1-c, d, e and P2-b were significantly increased, whereas the translation of the P1-a and P1-b constructs was barely activated (Figure 4D). This suggests the presence of not only the inhibitory sequence(s) between a and c but also the stimulatory element(s) in the shorter UTR forms, c, d and e. Taken together, these data indicate that the structure of 5'-UTRs of the P1 transcripts as well as the differential use of TSSs significantly affects their translation in response to stress. Figure 4.Efficiency of translation of the ATF3 mRNA isoforms from the P1 and P2 promoters. (A) Expression reporter plasmids encoding the ATF3 transcripts with various 5'-UTRs from the P1 (upper panel) and P2 promoters (lower panel) are shown. Arrows a through e indicate the 5'-ends of mRNAs corresponding multiple TSS of the P1 promoter in Figure 2B, and arrows a and b indicate the 5'-ends the P2 transcripts obtained from the database and reference (27). (B) Each plasmid was assayed for the in vitro translation as described in the Materials and methods section. The relative expression of ATF3 to plasmid without UTR is shown. (C) 293 cells were transfected with each expression plasmid, cultured for 24 h, and the ATF3 mRNA and protein generated from the transgene was measured as in the Materials and methods section. Relative efficiency of translation is the ratio of the ATF3 protein normalized to mRNA compared to that without 5'-UTR. (D) 293 cells were transfected with each plasmid, starved with 0.5% serum, followed by stimulation with 20% serum for 24 h or 50 mug/ml MMS for 12 h. After measurement of both ATF3 protein and mRNA generated from the transgene, relative efficiency of translation is shown as in (C). All the data from (B) through (D) represent the means with standard error bar of three independent experiments.
###end p 42
###begin p 43
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 83 84 83 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 332 340 332 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 450 451 450 451 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 486 494 486 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 624 625 624 625 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 937 938 937 938 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
Efficiency of translation of the ATF3 mRNA isoforms from the P1 and P2 promoters. (A) Expression reporter plasmids encoding the ATF3 transcripts with various 5'-UTRs from the P1 (upper panel) and P2 promoters (lower panel) are shown. Arrows a through e indicate the 5'-ends of mRNAs corresponding multiple TSS of the P1 promoter in Figure 2B, and arrows a and b indicate the 5'-ends the P2 transcripts obtained from the database and reference (27). (B) Each plasmid was assayed for the in vitro translation as described in the Materials and methods section. The relative expression of ATF3 to plasmid without UTR is shown. (C) 293 cells were transfected with each expression plasmid, cultured for 24 h, and the ATF3 mRNA and protein generated from the transgene was measured as in the Materials and methods section. Relative efficiency of translation is the ratio of the ATF3 protein normalized to mRNA compared to that without 5'-UTR. (D) 293 cells were transfected with each plasmid, starved with 0.5% serum, followed by stimulation with 20% serum for 24 h or 50 mug/ml MMS for 12 h. After measurement of both ATF3 protein and mRNA generated from the transgene, relative efficiency of translation is shown as in (C). All the data from (B) through (D) represent the means with standard error bar of three independent experiments.
###end p 43
###begin title 44
###xml 62 67 <span type="species:ncbi:9606">human</span>
Constitutive activation of the P1 promoter in ATF3-expressing human cancer cells
###end title 44
###begin p 45
###xml 130 135 130 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23 B24 B25">23&#8211;25</xref>
###xml 237 242 237 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23 B24 B25">23&#8211;25</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 373 381 373 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 831 839 831 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1279 1283 1279 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1296 1304 1296 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1428 1430 1428 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 1906 1910 1906 1910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1996 2005 1996 2005 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 2105 2106 2105 2106 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2415 2423 2415 2423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 2453 2457 2453 2457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 2502 2507 2502 2507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 2510 2511 2510 2511 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2846 2847 2846 2847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2885 2886 2885 2886 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 3216 3220 3216 3220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 2005 3461 2005 3461 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="46">Constitutive activation of the upstream P1 promoter in human prostate and Hodgkin RS cancer cells. (<bold>A</bold>) The expression level of ATF3 protein in DU145 (lane 1), PC-3 (lane 2), LNCaP (lane 3), DAUDI (lane 4), MOLT4 (lane 5), Hodgkin RS L428 (lane 6) or L540 (lane 7) cells was measured by western blot (upper panel). In the lower panel, total RNAs from these cells were assayed for the P1 or P2 transcripts as in <xref ref-type="fig" rid="F3">Figure 3</xref>A. Relative expression of the <italic>ATF3</italic> transcripts represents the ratio to that of <italic>GAPDH</italic>. (<bold>B</bold>) LNCaP, L428 or L540 cells were transfected with control siRNA oligos (siCtl, lane 1), or specific for the P1 (siP1, lane 2) or P2 transcript (siP2, lane 3), cultured for 48 h and assayed for the P1 and P2 transcripts or ATF3 protein. The relative expression of the P1 and P2 transcripts is shown as per cent of the control (siCtl). *<italic>P</italic> &lt; 0.05 compared with control siCtl. (<bold>C</bold>) LNCaP (filled circle, open circle) or DU145 (filled triangle, open triangle) cells were fixed with formaldehyde and immunoprecipitated using anti-RNA polymerase II (upper panel) or anti-Leo1 antibody (lower panel) as in Materials and methods section. Immunoprecipitated DNA was measured by quantitative PCR throughout the human <italic>ATF3</italic> gene locus and expressed as percent of the input DNA for the control IgG (open) and specific antibodies (closed), respectively. All the data from (A) through (C) represent the means of three independent experiments with standard error bars.</p>
###xml 2005 3461 2005 3461 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="46">Constitutive activation of the upstream P1 promoter in human prostate and Hodgkin RS cancer cells. (<bold>A</bold>) The expression level of ATF3 protein in DU145 (lane 1), PC-3 (lane 2), LNCaP (lane 3), DAUDI (lane 4), MOLT4 (lane 5), Hodgkin RS L428 (lane 6) or L540 (lane 7) cells was measured by western blot (upper panel). In the lower panel, total RNAs from these cells were assayed for the P1 or P2 transcripts as in <xref ref-type="fig" rid="F3">Figure 3</xref>A. Relative expression of the <italic>ATF3</italic> transcripts represents the ratio to that of <italic>GAPDH</italic>. (<bold>B</bold>) LNCaP, L428 or L540 cells were transfected with control siRNA oligos (siCtl, lane 1), or specific for the P1 (siP1, lane 2) or P2 transcript (siP2, lane 3), cultured for 48 h and assayed for the P1 and P2 transcripts or ATF3 protein. The relative expression of the P1 and P2 transcripts is shown as per cent of the control (siCtl). *<italic>P</italic> &lt; 0.05 compared with control siCtl. (<bold>C</bold>) LNCaP (filled circle, open circle) or DU145 (filled triangle, open triangle) cells were fixed with formaldehyde and immunoprecipitated using anti-RNA polymerase II (upper panel) or anti-Leo1 antibody (lower panel) as in Materials and methods section. Immunoprecipitated DNA was measured by quantitative PCR throughout the human <italic>ATF3</italic> gene locus and expressed as percent of the input DNA for the control IgG (open) and specific antibodies (closed), respectively. All the data from (A) through (C) represent the means of three independent experiments with standard error bars.</p></caption>
###xml 3461 3461 3461 3461 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn1082f5a"/>
###xml 3461 3461 3461 3461 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn1082f5b"/>
###xml 1996 3461 1996 3461 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="46">Constitutive activation of the upstream P1 promoter in human prostate and Hodgkin RS cancer cells. (<bold>A</bold>) The expression level of ATF3 protein in DU145 (lane 1), PC-3 (lane 2), LNCaP (lane 3), DAUDI (lane 4), MOLT4 (lane 5), Hodgkin RS L428 (lane 6) or L540 (lane 7) cells was measured by western blot (upper panel). In the lower panel, total RNAs from these cells were assayed for the P1 or P2 transcripts as in <xref ref-type="fig" rid="F3">Figure 3</xref>A. Relative expression of the <italic>ATF3</italic> transcripts represents the ratio to that of <italic>GAPDH</italic>. (<bold>B</bold>) LNCaP, L428 or L540 cells were transfected with control siRNA oligos (siCtl, lane 1), or specific for the P1 (siP1, lane 2) or P2 transcript (siP2, lane 3), cultured for 48 h and assayed for the P1 and P2 transcripts or ATF3 protein. The relative expression of the P1 and P2 transcripts is shown as per cent of the control (siCtl). *<italic>P</italic> &lt; 0.05 compared with control siCtl. (<bold>C</bold>) LNCaP (filled circle, open circle) or DU145 (filled triangle, open triangle) cells were fixed with formaldehyde and immunoprecipitated using anti-RNA polymerase II (upper panel) or anti-Leo1 antibody (lower panel) as in Materials and methods section. Immunoprecipitated DNA was measured by quantitative PCR throughout the human <italic>ATF3</italic> gene locus and expressed as percent of the input DNA for the control IgG (open) and specific antibodies (closed), respectively. All the data from (A) through (C) represent the means of three independent experiments with standard error bars.</p></caption><graphic xlink:href="gkn1082f5a"/><graphic xlink:href="gkn1082f5b"/></fig>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 399 404 <span type="species:ncbi:9606">human</span>
###xml 1947 1952 <span type="species:ncbi:9606">human</span>
###xml 2060 2065 <span type="species:ncbi:9606">human</span>
###xml 3210 3215 <span type="species:ncbi:9606">human</span>
ATF3 is constitutively overexpressed in several forms of human cancer cells such as prostate, Hodgkin disease and mammary tumors (23-25), and the elevated ATF3 expression correlates to the cell proliferation, progression and metastasis (23-25,39). To clarify the functional role of alternate promoters in these cells, we examined the expression of ATF3 from each promoter. Figure 5A showed that, in human prostate cancer LNCaP and Hodgkin Reed-Sternberg L428 and L540 cells, the amount of ATF3 protein was increased as reported (23,24). Most significantly, the P1 transcript was dominantly expressed in these cells compared to DU145 and PC3 or DAUDI and MOLT 4 cells, demonstrating that the P1 promoter is selectively activated. To further clarify the actual involvement of each promoter, we knocked down the P1 or P2 transcripts. Figure 5B clearly showed the knockdown of the P1 transcript drastically suppressed the expression of the ATF3 protein along with the P1 transcript in LNCaP, L428 and L540 cells, whereas the P2 knockdown had only marginally effect. The data strongly support that the P1 promoter has a direct contribution to the elevated expression of ATF3 in these cancer cells. We next performed ChIP assay to examine the association of RNA polymerase II with the ATF3 gene locus. Figure 5C showed that, in LNCaP cells, RNA polymerase II and Leo1, a component of PAF1 complex in the elongating RNA polymerase II (40), were clearly recruited through the P1 promoter to downstream regions, compared to -5-kb region and the control IgG, whereas the Leo1 signal peaked at around +10-kb region. In contrast, DU145 cells that had lower expression of ATF3 did not show significant recruitment of RNA polymerase II. The increased association of RNA polymerase II to the P1 promoter region was also observed in Hodgkin L428 cells (). These data unambiguously indicate the upstream P1 promoter of the ATF3 gene is constitutively activated in human prostate and Hodgkin Reed-Sternberg cells. Figure 5.Constitutive activation of the upstream P1 promoter in human prostate and Hodgkin RS cancer cells. (A) The expression level of ATF3 protein in DU145 (lane 1), PC-3 (lane 2), LNCaP (lane 3), DAUDI (lane 4), MOLT4 (lane 5), Hodgkin RS L428 (lane 6) or L540 (lane 7) cells was measured by western blot (upper panel). In the lower panel, total RNAs from these cells were assayed for the P1 or P2 transcripts as in Figure 3A. Relative expression of the ATF3 transcripts represents the ratio to that of GAPDH. (B) LNCaP, L428 or L540 cells were transfected with control siRNA oligos (siCtl, lane 1), or specific for the P1 (siP1, lane 2) or P2 transcript (siP2, lane 3), cultured for 48 h and assayed for the P1 and P2 transcripts or ATF3 protein. The relative expression of the P1 and P2 transcripts is shown as per cent of the control (siCtl). *P < 0.05 compared with control siCtl. (C) LNCaP (filled circle, open circle) or DU145 (filled triangle, open triangle) cells were fixed with formaldehyde and immunoprecipitated using anti-RNA polymerase II (upper panel) or anti-Leo1 antibody (lower panel) as in Materials and methods section. Immunoprecipitated DNA was measured by quantitative PCR throughout the human ATF3 gene locus and expressed as percent of the input DNA for the control IgG (open) and specific antibodies (closed), respectively. All the data from (A) through (C) represent the means of three independent experiments with standard error bars.
###end p 45
###begin p 46
###xml 100 101 100 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 410 418 410 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 497 502 497 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 505 506 505 506 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 841 842 841 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 880 881 880 881 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1211 1215 1211 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 1205 1210 <span type="species:ncbi:9606">human</span>
Constitutive activation of the upstream P1 promoter in human prostate and Hodgkin RS cancer cells. (A) The expression level of ATF3 protein in DU145 (lane 1), PC-3 (lane 2), LNCaP (lane 3), DAUDI (lane 4), MOLT4 (lane 5), Hodgkin RS L428 (lane 6) or L540 (lane 7) cells was measured by western blot (upper panel). In the lower panel, total RNAs from these cells were assayed for the P1 or P2 transcripts as in Figure 3A. Relative expression of the ATF3 transcripts represents the ratio to that of GAPDH. (B) LNCaP, L428 or L540 cells were transfected with control siRNA oligos (siCtl, lane 1), or specific for the P1 (siP1, lane 2) or P2 transcript (siP2, lane 3), cultured for 48 h and assayed for the P1 and P2 transcripts or ATF3 protein. The relative expression of the P1 and P2 transcripts is shown as per cent of the control (siCtl). *P < 0.05 compared with control siCtl. (C) LNCaP (filled circle, open circle) or DU145 (filled triangle, open triangle) cells were fixed with formaldehyde and immunoprecipitated using anti-RNA polymerase II (upper panel) or anti-Leo1 antibody (lower panel) as in Materials and methods section. Immunoprecipitated DNA was measured by quantitative PCR throughout the human ATF3 gene locus and expressed as percent of the input DNA for the control IgG (open) and specific antibodies (closed), respectively. All the data from (A) through (C) represent the means of three independent experiments with standard error bars.
###end p 46
###begin title 47
###xml 30 35 <span type="species:ncbi:9606">human</span>
Chromatin modification of the human ATF3 gene in cancer cells
###end title 47
###begin p 48
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 158 166 158 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 608 616 605 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 620 628 617 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 870 874 867 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1018 1027 1015 1024 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 1066 1070 1063 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1116 1117 1113 1114 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1335 1339 1332 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1361 1366 1358 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1518 1519 1512 1513 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1737 1741 1731 1735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 1027 1946 1024 1940 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="49">Histone modifications across the human <italic>ATF3</italic> gene locus in LNCaP and Hodgkin L428 cells. (<bold>A</bold>) ChIP assay was performed in LNCaP, DU145, L428, or DAUDI cells using anti-panacetyl H3, anti-trimethyl H3K4 or anti-trimethyl H3K9 antibodies as in Materials and methods section. The P1 and P2 promoter region of the <italic>ATF3</italic> gene and the control <italic>GAPDH</italic> gene was amplified and analyzed by gel electrophoresis. In L428 and DAUDI cells, the promoter region of the human &#946;-globin gene was also examined. (<bold>B</bold>) Immunoprecipitated DNA by anti-panacetyl H3 or anti-trimethyl H3K4 antibodies of LNCaP (filled circle, open circle), DU145 (filled traingle, open triangle) cells was measured by quantitative PCR throughout the human <italic>ATF3</italic> gene locus, and expressed as percent of the input. Data represent the means of three independent experiments with standard error bars for control IgG (open) and specific antibodies (closed), respectively.</p>
###xml 1027 1946 1024 1940 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="49">Histone modifications across the human <italic>ATF3</italic> gene locus in LNCaP and Hodgkin L428 cells. (<bold>A</bold>) ChIP assay was performed in LNCaP, DU145, L428, or DAUDI cells using anti-panacetyl H3, anti-trimethyl H3K4 or anti-trimethyl H3K9 antibodies as in Materials and methods section. The P1 and P2 promoter region of the <italic>ATF3</italic> gene and the control <italic>GAPDH</italic> gene was amplified and analyzed by gel electrophoresis. In L428 and DAUDI cells, the promoter region of the human &#946;-globin gene was also examined. (<bold>B</bold>) Immunoprecipitated DNA by anti-panacetyl H3 or anti-trimethyl H3K4 antibodies of LNCaP (filled circle, open circle), DU145 (filled traingle, open triangle) cells was measured by quantitative PCR throughout the human <italic>ATF3</italic> gene locus, and expressed as percent of the input. Data represent the means of three independent experiments with standard error bars for control IgG (open) and specific antibodies (closed), respectively.</p></caption>
###xml 1946 1946 1940 1940 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn1082f6"/>
###xml 1018 1946 1015 1940 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="49">Histone modifications across the human <italic>ATF3</italic> gene locus in LNCaP and Hodgkin L428 cells. (<bold>A</bold>) ChIP assay was performed in LNCaP, DU145, L428, or DAUDI cells using anti-panacetyl H3, anti-trimethyl H3K4 or anti-trimethyl H3K9 antibodies as in Materials and methods section. The P1 and P2 promoter region of the <italic>ATF3</italic> gene and the control <italic>GAPDH</italic> gene was amplified and analyzed by gel electrophoresis. In L428 and DAUDI cells, the promoter region of the human &#946;-globin gene was also examined. (<bold>B</bold>) Immunoprecipitated DNA by anti-panacetyl H3 or anti-trimethyl H3K4 antibodies of LNCaP (filled circle, open circle), DU145 (filled traingle, open triangle) cells was measured by quantitative PCR throughout the human <italic>ATF3</italic> gene locus, and expressed as percent of the input. Data represent the means of three independent experiments with standard error bars for control IgG (open) and specific antibodies (closed), respectively.</p></caption><graphic xlink:href="gkn1082f6"/></fig>
###xml 1060 1065 <span type="species:ncbi:9606">human</span>
###xml 1475 1480 <span type="species:ncbi:9606">human</span>
###xml 1731 1736 <span type="species:ncbi:9606">human</span>
Constitutive activation of the upstream P1 promoter in cancer cells prompted us to examine the chromatin modifications of the ATF3 gene promoter. As shown in Figure 6A, antibodies against the pan-acetylated histone H3 and trimethylated H3K4me3 efficiently immunoprecipitated the P1 promoter region in LNCaP and Hodgkin 428 cells, compared to DU145 or DAUDI cells. In contrast, no significant H3K9 methylation was observed at the ATF3 P1 promoter region in LNCaP or L428 cells. As an inactivated gene control, the ChIP signal of H3K9 methylation at the beta-globin gene promoter in L428 cells was also shown (Figure 6A). Figure 6B and  further showed that the significant pan-acetylation and K4 trimethylation of H3 were detected from the P1 promoter to +10-kb region compared to other region in LNCaP and L428 cells, respectively. Taken together, the P1 promoter of the ATF3 gene in LNCaP and Hodgkin L428 cells has an active chromatin configuration associated with the histone H3 acetylation and H3K4 trimethylation. Figure 6.Histone modifications across the human ATF3 gene locus in LNCaP and Hodgkin L428 cells. (A) ChIP assay was performed in LNCaP, DU145, L428, or DAUDI cells using anti-panacetyl H3, anti-trimethyl H3K4 or anti-trimethyl H3K9 antibodies as in Materials and methods section. The P1 and P2 promoter region of the ATF3 gene and the control GAPDH gene was amplified and analyzed by gel electrophoresis. In L428 and DAUDI cells, the promoter region of the human beta-globin gene was also examined. (B) Immunoprecipitated DNA by anti-panacetyl H3 or anti-trimethyl H3K4 antibodies of LNCaP (filled circle, open circle), DU145 (filled traingle, open triangle) cells was measured by quantitative PCR throughout the human ATF3 gene locus, and expressed as percent of the input. Data represent the means of three independent experiments with standard error bars for control IgG (open) and specific antibodies (closed), respectively.
###end p 48
###begin p 49
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 89 90 89 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 491 492 488 489 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 710 714 707 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 33 38 <span type="species:ncbi:9606">human</span>
###xml 448 453 <span type="species:ncbi:9606">human</span>
###xml 704 709 <span type="species:ncbi:9606">human</span>
Histone modifications across the human ATF3 gene locus in LNCaP and Hodgkin L428 cells. (A) ChIP assay was performed in LNCaP, DU145, L428, or DAUDI cells using anti-panacetyl H3, anti-trimethyl H3K4 or anti-trimethyl H3K9 antibodies as in Materials and methods section. The P1 and P2 promoter region of the ATF3 gene and the control GAPDH gene was amplified and analyzed by gel electrophoresis. In L428 and DAUDI cells, the promoter region of the human beta-globin gene was also examined. (B) Immunoprecipitated DNA by anti-panacetyl H3 or anti-trimethyl H3K4 antibodies of LNCaP (filled circle, open circle), DU145 (filled traingle, open triangle) cells was measured by quantitative PCR throughout the human ATF3 gene locus, and expressed as percent of the input. Data represent the means of three independent experiments with standard error bars for control IgG (open) and specific antibodies (closed), respectively.
###end p 49
###begin title 50
DISCUSSION
###end title 50
###begin p 51
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 122 127 <span type="species:ncbi:9606">human</span>
###xml 307 312 <span type="species:ncbi:9606">human</span>
In the present report, we described the structural and functional properties of the upstream alternate promoter P1 of the human ATF3 gene. The P1 promoter is used differently from the P2 promoter at the transcriptional and translational level in stress response. Moreover, it is constitutively activated in human cancer cells associated with the active chromatin configuration, as a consequence, followed by the elevated expression of ATF3.
###end p 51
###begin p 52
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 614 616 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 816 824 792 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1386 1388 1350 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 475 480 <span type="species:ncbi:9606">human</span>
###xml 485 490 <span type="species:ncbi:10090">mouse</span>
###xml 699 704 <span type="species:ncbi:9606">human</span>
###xml 709 714 <span type="species:ncbi:10090">mouse</span>
###xml 1038 1043 <span type="species:ncbi:9606">human</span>
###xml 1048 1053 <span type="species:ncbi:10090">mouse</span>
###xml 1505 1510 <span type="species:ncbi:9606">human</span>
###xml 1515 1520 <span type="species:ncbi:10090">mouse</span>
Kimura et al. (35) reported that at least 52% of the human genes contain putative alternative promoters, with 3.1 alternative promoters per gene on average, and the genes subject to regulation by alternative promoters are enriched in those encoding signal transduction-related proteins. Indeed, the ATF3 gene encodes a transcription factor that is induced and plays role in various stress response and signaling. The P1 promoter of the ATF3 gene was highly conserved between human and mouse, which localizes approximately43.5-kb and approximately34.5- kb upstream of the previously reported canonical promoter P2 (30), respectively. The P1 promoter has several properties that are conserved between human and mouse. (i) Sequence of the promoter region as well as the junction of exon A-1 and B are highly conserved (Figure 1C and 2B). The putative TATA motif is localized approximately30 base upstream from the major TSS, and other binding motifs for AP1, ATF/CREB, NF-kB, E2F, or p53 are conserved. (ii) Multiple TSSs are present in the human and mouse genes. (iii) The P1 promoter has less stretch of CG dinucleotides, whereas the P2 promoter contains at least three CpG islands within the 2-kb region of the promoter. This structural difference between the P1 and P2 promoters is of intrigue, because there is one CpG-island-containing promoter per 2.6 CpG-less alternate promoters (35). Overall, the structural properties of the P1 promoter strongly support that it is evolutionally conserved between human and mouse, and has distinct control mechanism.
###end p 52
###begin p 53
###xml 236 244 236 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 630 634 630 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 36 41 <span type="species:ncbi:9606">human</span>
The P1 promoter of the ATF3 gene in human cells was activated by various stimuli including serum, DNA damage and oxidoreductive stress, and the extent of the P1 promoter activation was comparable to or exceeded that of the P2 promoter (Figure 3). Indeed, the 5'-flanking region of the P1 promoter contains several motifs for transcription factors involved in the signaling of stress stimuli, including the binding motifs for ATF/CRE, AP1, NF-kB, E2F, c-Myc or p53. Whereas the significance and implication of these motifs in each stress response was not addressed in this report, it is also possible that a common motif(s) in the ATF3 gene locus confers stress response on both the P1 and P2 promoters. This is an important issue and must await further study.
###end p 53
###begin p 54
###xml 172 181 172 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figures 2</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 344 353 344 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3 gene</italic>
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 844 847 844 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1265 1272 1265 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1520 1527 1520 1527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Various 5'-UTRs of the P1 transcripts contain the features of poorly translated mRNA, that is relatively long 5'-UTR with multiple upstream AUGs (uAUGs) and upstream ORFs (Figures 2B and 4A). These features are often found in mRNAs encoding regulatory proteins like proto-oncogenes or growth factor (41), consistent with biological role of the ATF3 gene. In our translational reporter assay, however, sequential mutations of uAUGs in the 5'-UTR of the P1 transcrips had no significant effect on their translation (data not shown). The assay revealed the presence of the inhibitory region in the longest 5'-UTR as well as the stimulatory element(s) in the shorter 5'-UTRs, implicating a role of trans-acting factor(s) interacting with these element(s) in the 5'-UTR in stress response. The identification of such factor(s) and the corresponding cis-element(s) is an important issue of further study. It should be noted that the present study employed the reporters containing only the different 5'-UTRs, since the P1 and P2 transcripts have the common sequence from the coding through the 3'-UTR (NM_001030287 and NM_001674). However, it is possible that the 3'-UTR may contribute to the regulation, since 3'-UTR is well known to affect the translational efficiency in vivo. More importantly, the 5'-RACE analysis revealed the differential usage of TSSs in MMS- and serum-treated cells. Thus, it is highly likely that the selection or shift of the TSSs within the P1 promoter also regulates the efficiency of translation in vivo.
###end p 54
###begin p 55
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9 B10 B11 B12">9&#8211;12</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 316 321 316 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23 B24 B25 B26">23&#8211;26</xref>
###xml 715 723 715 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 732 740 732 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1032 1034 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 1322 1325 1322 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1556 1558 1556 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1671 1679 1671 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 1521 1524 <span type="species:ncbi:10116">rat</span>
Early studies showed that the ATF3 induction correlates with cell-detrimental outcome such as cell cycle arrest or apoptosis, thus providing an idea that it is death factor (9-12). However, ATF3 is also implicated in cell proliferation (13,15,18,22), transformation (19), cell survival (20,21) and tumorigenesis (14,23-26). Our present study demonstrated for the first time that the P1 promoter is constitutively activated in human cancer cells with the elevated expression of ATF3 protein. In LNcaP and Hodgkin cancer cells, the chromatin structure of the P1 promoter region is remodeled and fixed to an active open state through the histone modification, including histone H3 acetylation and H3K4 trimethylation (Figure 6). As in Figure 3A, the serum response of the P2 promoter was more rapid but suppressed earlier than the P1 promoter. It is speculated that the P2 promoter responds to serum, but is suppressed by the transcription from the upstream promoter P1 through a mechanism called delayed transcriptional interference (42), while it is also possible that the splicing of the transcripts is differently regulated. At this moment, however, it is not known to what extent these mechanisms could be applied to constitutive activation of the P1 promoter in LNCaP and Hodgkin cancer cells. It is also unlikely that cis-element(s) of the promoter responsible for serum response is the only mechanism by which the P1 promoter is constitutively activated in cancer cells, since the P2 promoter is induced by serum in rat fibroblasts via ATF/CRE motif (22), and the reporter activity driven by the P2 promoter was activated by serum as efficiently as the P1 promoter (Figure 3D).
###end p 55
###begin p 56
###xml 168 172 168 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 456 460 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATF3</italic>
###xml 358 363 <span type="species:ncbi:9606">human</span>
###xml 450 455 <span type="species:ncbi:9606">human</span>
In conclusion, the present study for the first time described the molecular and functional properties of the upstream alternate promoter P1 of the stress response gene ATF3. Of intrigue, the expression from the P1 promoter is regulated at both the transcriptional and translational levels, and is constitutively activated with altered chromatin structure in human cancer cells. The differential usage and regulation of the alternate promoters of the human ATF3 gene adds an important dimension to the control mechanism by which it plays dual role in determining cell fate during stress response and oncogenesis.
###end p 56
###begin title 57
SUPPLEMENTARY DATA
###end title 57
###begin p 58
 are available at NAR Online.
###end p 58
###begin title 59
FUNDING
###end title 59
###begin p 60
Research on Priority Areas from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [18012015, 18055008] to S.K. in part. Funding for open access charge: Ministry of Education, Culture, Sports, Science, and Technology of Japan.
###end p 60
###begin p 61
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 61
###begin title 62
Supplementary Material
###end title 62
###begin title 63
[Supplementary Data]
###end title 63
###begin title 64
ACKNOWLEDGEMENTS
###end title 64
###begin p 65
We thank Dr Nevins and Dr Jenuwein for their gifts of valuable plasmids, Dr Yamaoka for his helpful discussion, Ms Y. Hosaka and A. Nakamura for their technical assistance.
###end p 65
###begin title 66
REFERENCES
###end title 66
###begin article-title 67
Complex controls: the role of alternative promoters in mammalian genomes
###end article-title 67
###begin article-title 68
The functional consequences of alternative promoter use in mammalian genomes
###end article-title 68
###begin article-title 69
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 122 137 <span type="species:ncbi:10090">transgenic mice</span>
A 500-bp region, approximately40kb upstream of the human CYP19 (aromatase) gene, mediates placenta-specific expression in transgenic mice
###end article-title 69
###begin article-title 70
An alternate promoter in the glucokinase gene is active in the pancreatic beta cell
###end article-title 70
###begin article-title 71
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human fibroblast growth factor 1 gene expression in vascular smooth muscle cells is modulated via an alternate promoter in response to serum and phorbol ester
###end article-title 71
###begin article-title 72
Virtues and woes of AchE alternative splicing in stress-related neuropathologies
###end article-title 72
###begin article-title 73
p53/-63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress
###end article-title 73
###begin article-title 74
Stress-induced translation of ATF5 mRNA is regulated by the 5'-untranslated region
###end article-title 74
###begin article-title 75
ATF3 and stress responses
###end article-title 75
###begin article-title 76
Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney
###end article-title 76
###begin article-title 77
###xml 48 53 <span type="species:ncbi:9606">human</span>
Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH2 terminal kinase and promoter response element
###end article-title 77
###begin article-title 78
ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cell growth
###end article-title 78
###begin article-title 79
A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells
###end article-title 79
###begin article-title 80
ATF3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis
###end article-title 80
###begin article-title 81
Identification of LRF-1, a leucine-zipper protein that is rapidly and highly induced in regenerating liver
###end article-title 81
###begin article-title 82
The immediate-early growth response in regenerating liver and insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 cells and identification of 41 novel immediate-early genes
###end article-title 82
###begin article-title 83
###xml 47 52 <span type="species:ncbi:9606">human</span>
The transcriptional program in the response of human fibroblasts to serum
###end article-title 83
###begin article-title 84
Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes
###end article-title 84
###begin article-title 85
###xml 47 52 <span type="species:ncbi:9031">chick</span>
Transcription factor ATF3 partially transforms chick embryo fibroblasts by promoting growth factor-independent proliferation
###end article-title 85
###begin article-title 86
###xml 69 74 <span type="species:ncbi:9606">human</span>
Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription
###end article-title 86
###begin article-title 87
Expression of the activating transcription factor ATF3 prevents c-Jun N-terminal kinase-induced neuronal death by promoting heat shock protein 27 expression and akt activation
###end article-title 87
###begin article-title 88
Stress response gene ATF3 is a target of c-myc in serum-induced cell proliferation
###end article-title 88
###begin article-title 89
###xml 80 85 <span type="species:ncbi:9606">human</span>
The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer
###end article-title 89
###begin article-title 90
Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells
###end article-title 90
###begin article-title 91
A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development
###end article-title 91
###begin article-title 92
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Epidermal hyperplasia and oral carcinoma in mice overexpressing the transcription factor ATF3 in basal epithelial cells
###end article-title 92
###begin article-title 93
Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4
###end article-title 93
###begin article-title 94
###xml 15 19 <span type="species:ncbi:10366?0.7619047619047619|species:ncbi:12138?0.0056022408963585435">MCMV</span>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
ATF3 regulates MCMV infection in mice by modulating IFN-gamma expression in natural killer cells
###end article-title 94
###begin article-title 95
Activating transcription factor 3 is a negative regulator of allergic pulmonary inflammation
###end article-title 95
###begin article-title 96
ATF3 gene. Genomic organization, promoter, and regulation
###end article-title 96
###begin article-title 97
Activation of the ATF3 gene through a co-ordinated amino acid-sensing response programme that controls transcriptional regulation of responsive genes following amino acid limitation
###end article-title 97
###begin article-title 98
###xml 34 39 <span type="species:ncbi:9606">human</span>
Transcriptional activation of the human stress-inducible transcriptional repressor ATF3 gene promoter by p53
###end article-title 98
###begin article-title 99
Activating transcription factor 3 and early growth response-1 are the novel targets of LY294002 in a PI3K independent pathway
###end article-title 99
###begin article-title 100
The regulation of ATF3 gene expression by mitogen-activated protein kinases
###end article-title 100
###begin article-title 101
###xml 132 137 <span type="species:ncbi:9606">human</span>
Diversification of transcriptional modulation: large scale identification and characterization of putative alternative promoters of human genes
###end article-title 101
###begin article-title 102
Protein measurement with the folin phenol reagent
###end article-title 102
###begin article-title 103
ATF3 and ATF3deltaZip. Transcriptional repression versus activation by alternatively spliced isoform
###end article-title 103
###begin article-title 104
###xml 73 79 <span type="species:ncbi:10090">murine</span>
Identification of a lipopolysaccharide inducible transcription factor in murine macrophages
###end article-title 104
###begin article-title 105
The tumor metastasis suppressor gene Drg-1 down-regulates the expression of ATF3 in prostate cancer
###end article-title 105
###begin article-title 106
The Paf1 complex physically and functionally associates with transcription elongation factors in vivo
###end article-title 106
###begin article-title 107
###xml 23 28 <span type="species:ncbi:9606">human</span>
CART classification of human 5' UTR sequences
###end article-title 107
###begin article-title 108
Transcriptional interference - a crash course
###end article-title 108

